On August 4, 2023, I bought additional 2 shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) stock, paying $9.98 per share for our long-term dividend stock portfolio
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
We are now holding 4 shares of TEVA in our stock portfolio.
Unlike, most of the other stocks from our portfolio, TEVA is not a dividend payer, I keep buying this stock, for value growth and covered call writting
Using dollar-cost averaging our average cost per TEVA share is $9.33
To finance this purchase I was actually selling a put option, and bought this stock from the premium received. See: Sold 1 Put Option on TEVA Stock – 4.10% potential income return in 63 days (23.73% annualized)
96 shares to go once we will be able to start selling covered calls and generate extra income from TEVA stock. I don't have a set time frame when to get there, as I'm planning to buy these stocks from the put options premiums. It could take some 2-3 years once I will get there, or much sooner if the stock will get assigned.
Interested to learn more about our covered call trades? Sign up for the newsletter at coveredcalls.reinisfischer.com